Research & Development



  “也不知道能不能弄死這個老家伙,不過啊,我走的時候老家伙的臉上有血色了,應該是藥起作用了。他的身子骨已經油盡燈枯了,這時候再用虎狼藥激發一下,應該能要了他的命吧?”   伊秩斜重新坐回床榻,瞅了一眼正在穿衣的如意問道︰“問問你的主人,她知不知道這支軍隊的來歷?”青娱乐在线品盛宴   自從跟漢軍完成了那樁交易,拿回來了白骨將軍烏利亞的人頭,就受到了右谷蠡王的獎賞,授權他,可以跟漢軍交易,來為右谷蠡王積累財富。青娱乐极品视觉盛宴   現在,他發現自己居然無法越過屠耆王這做高山,一旦殺死了屠耆王,他統治匈奴的人心基礎就會完全坍塌。   或許,也需要一個能隨時殺死軍臣單于的人。青娱乐在线   “劉陵……”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo